BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38484555)

  • 1. Desulfovibrio desulfuricans and its derived metabolites confer resistance to FOLFOX through METTL3.
    Li G; Liu H; Yu Y; Wang Q; Yang C; Yan Y; Wang F; Mao Y
    EBioMedicine; 2024 Apr; 102():105041. PubMed ID: 38484555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of BIRC7/Livin, Bcl-2, p53, Annexin V, PD-L1, DARC, MSH2 and PMS2 in colorectal cancer treated with FOLFOX chemotherapy with or without aspirin.
    Faruk M; Ibrahim S; Aminu SM; Adamu A; Abdullahi A; Suleiman AM; Rafindadi AH; Mohammed A; Iliyasu Y; Idoko J; Saidu R; Randawa AJ; Musa HS; Ntekim A; Shah KZ; Abubakar S; Adoke KU; Manko M; Awasum CA
    PLoS One; 2021; 16(1):e0245581. PubMed ID: 33465114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fecal Microbiota Transplantation Prevents Intestinal Injury, Upregulation of Toll-Like Receptors, and 5-Fluorouracil/Oxaliplatin-Induced Toxicity in Colorectal Cancer.
    Chang CW; Lee HC; Li LH; Chiang Chiau JS; Wang TE; Chuang WH; Chen MJ; Wang HY; Shih SC; Liu CY; Tsai TH; Chen YJ
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31936237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases.
    Andreou A; Kopetz S; Maru DM; Chen SS; Zimmitti G; Brouquet A; Shindoh J; Curley SA; Garrett C; Overman MJ; Aloia TA; Vauthey JN
    Ann Surg; 2012 Oct; 256(4):642-50. PubMed ID: 22968062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nuclear orphan receptor NR4A2 confers chemoresistance and predicts unfavorable prognosis of colorectal carcinoma patients who received postoperative chemotherapy.
    Han Y; Cai H; Ma L; Ding Y; Tan X; Liu Y; Su T; Yu Y; Chang W; Zhang H; Fu C; Cao G
    Eur J Cancer; 2013 Nov; 49(16):3420-30. PubMed ID: 23809767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
    Hong YS; Nam BH; Kim KP; Kim JE; Park SJ; Park YS; Park JO; Kim SY; Kim TY; Kim JH; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW
    Lancet Oncol; 2014 Oct; 15(11):1245-53. PubMed ID: 25201358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of preoperative FOLFOX chemotherapy on CCL20/CCR6 expression in colorectal liver metastases.
    Rubie C; Frick VO; Ghadjar P; Wagner M; Justinger C; Graeber S; Sperling J; Kollmar O; Schilling MK
    World J Gastroenterol; 2011 Jul; 17(26):3109-16. PubMed ID: 21912453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of the Relation between the Expression of Oxaliplatin Transporters in Colorectal Cancer and Response to FOLFOX-4 Adjuvant Chemotherapy: A Case Control Study.
    Le Roy B; Tixier L; Pereira B; Sauvanet P; Buc E; Pétorin C; Déchelotte P; Pezet D; Balayssac D
    PLoS One; 2016; 11(2):e0148739. PubMed ID: 26859833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. METTL3 antagonizes 5‑FU chemotherapy and confers drug resistance in colorectal carcinoma.
    Li M; Xia M; Zhang Z; Tan Y; Li E; Guo Z; Fang M; Zhu Y; Hu Z
    Int J Oncol; 2022 Sep; 61(3):. PubMed ID: 35856434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Two Subgroups of FOLFOX Resistance Patterns and Prediction of FOLFOX Response in Colorectal Cancer Patients.
    Tian S; Wang F; Lu S; Chen G
    Cancer Invest; 2021 Jan; 39(1):62-72. PubMed ID: 33258714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Colorectal cancer cell-derived CCL20 recruits regulatory T cells to promote chemoresistance via FOXO1/CEBPB/NF-κB signaling.
    Wang D; Yang L; Yu W; Wu Q; Lian J; Li F; Liu S; Li A; He Z; Liu J; Sun Z; Yuan W; Zhang Y
    J Immunother Cancer; 2019 Aug; 7(1):215. PubMed ID: 31395078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The ZEB2-dependent EMT transcriptional programme drives therapy resistance by activating nucleotide excision repair genes ERCC1 and ERCC4 in colorectal cancer.
    Sreekumar R; Al-Saihati H; Emaduddin M; Moutasim K; Mellone M; Patel A; Kilic S; Cetin M; Erdemir S; Navio MS; Lopez MA; Curtis N; Yagci T; Primrose JN; Price BD; Berx G; Thomas GJ; Tulchinsky E; Mirnezami A; Sayan AE
    Mol Oncol; 2021 Aug; 15(8):2065-2083. PubMed ID: 33931939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apical Lymph Nodes in the Distant Metastases and Prognosis of Patients with Stage III Colorectal Cancer with Adequate Lymph Node Retrieval Following FOLFOX Adjuvant Chemotherapy.
    Tsai HL; Chen YT; Yeh YS; Huang CW; Ma CJ; Wang JY
    Pathol Oncol Res; 2019 Jul; 25(3):905-913. PubMed ID: 29299827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative sequence analysis of patient-matched primary colorectal cancer, metastatic, and recurrent metastatic tumors after adjuvant FOLFOX chemotherapy.
    Harada K; Okamoto W; Mimaki S; Kawamoto Y; Bando H; Yamashita R; Yuki S; Yoshino T; Komatsu Y; Ohtsu A; Sakamoto N; Tsuchihara K
    BMC Cancer; 2019 Mar; 19(1):255. PubMed ID: 30898102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic and predictive significance of long interspersed nucleotide element-1 methylation in advanced-stage colorectal cancer.
    Kaneko M; Kotake M; Bando H; Yamada T; Takemura H; Minamoto T
    BMC Cancer; 2016 Dec; 16(1):945. PubMed ID: 27955637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FOLFOX treatment response prediction in metastatic or recurrent colorectal cancer patients via machine learning algorithms.
    Lu W; Fu D; Kong X; Huang Z; Hwang M; Zhu Y; Chen L; Jiang K; Li X; Wu Y; Li J; Yuan Y; Ding K
    Cancer Med; 2020 Feb; 9(4):1419-1429. PubMed ID: 31893575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical impact of K-ras mutation in colorectal cancer patients treated with adjuvant FOLFOX.
    Chang MH; Lee IK; Si Y; Lee KS; Woo IS; Byun JH
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):317-23. PubMed ID: 20972872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KRAS as a predictor of poor prognosis and benefit from postoperative FOLFOX chemotherapy in patients with stage II and III colorectal cancer.
    Deng Y; Wang L; Tan S; Kim GP; Dou R; Chen D; Cai Y; Fu X; Wang L; Zhu J; Wang J
    Mol Oncol; 2015 Aug; 9(7):1341-7. PubMed ID: 25864038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Network meta-analysis of Chinese herb injections combined with FOLFOX chemotherapy in the treatment of advanced colorectal cancer.
    Ge L; Wang YF; Tian JH; Mao L; Zhang J; Zhang JH; Shen XP; Yang KH
    J Clin Pharm Ther; 2016 Aug; 41(4):383-91. PubMed ID: 27338003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreasing relapse in colorectal cancer patients treated with cetuximab by using the activating KRAS detection chip.
    Huang MY; Liu HC; Yen LC; Chang JY; Huang JJ; Wang JY; Lin SR
    Tumour Biol; 2014 Oct; 35(10):9639-47. PubMed ID: 24964961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.